FEB 11, 2016 03:22 PM PST

Treating TTP with Synthetic Antibodies

WRITTEN BY: Kara Marker
Rare but deadly, thrombotic thrombocytopenic purpura (TTP) is a disease where blood clots block the smallest blood vessels often leading to kidney failure, stroke, and heart disease. Over 4 million Americans are affected each year, either from hereditary or acquired forms of the disease.
 
Past the acute phase, TTP is relatively easily defeated with immunotherapy, said Paul Knöbl from the Medical University of Vienna. However, 10 to 20 percent of people do not survive the acute phase, even with plasma exchange therapy. In a new study published in the New England Journal of Medicine, Knöbl and other researchers from the Medical University of Vienna examined the capability of a synthesized antibody to reverse the impact of the disease.
 
Newly formed blood vessel within an occluded artery of the lower leg

 
TTP is characterized by a deficiency of an enzyme called ADAMST13 regardless of whether the disease was acquired or inherited. Without ADAMST13, another protein called von Willebrand is overexpressed and destructively so, binding platelets and inducing aggregation in blood vessels. Blood clots caused by TTP can lead to kidney failure, stroke, and heart disease.
 
Current plasma exchange therapy removes autoantibodies causing the ADAMST13 deficiency, removes overgrown von Willebrand protein complexes, and replenishes the body’s stock of ADAMST13. After a patient survives the acute phase, immunotherapy prevents continuous autoantibody formation. The synthesized antibody proposed by this study would be used for treatment both during and after the acute phase, instead targeting the masses of overactive von Willebrand protein. By blocking the protein’s interaction with platelets, the antibody reduces the severity of blood clots characterizing TTP to practically zero.
 
"In future this drug might also be used to treat similar diseases, which are jointly caused by overactivity of the von Willebrand factor, and therefore represents a new treatment option," said the Medical University of Vienna’s Bernd Jilma.
 
The antibody being studied is called “caplacizumab.”
 

Source: Medical University of Vienna, New England Journal of Medicine
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 21, 2019
Cardiology
AUG 21, 2019
Cardiovascular Risks Linked To Excessive Weight In Infancy
New research, from the University of Sydney, found excessive weight gain in children under two can lead to cardiovascular risk factors in teenage years.&nb...
AUG 21, 2019
Cardiology
AUG 21, 2019
Meditation May Be Helpful Addition To Care For Heart Disease Patients
Research has shown that stress is not good for the heart. To combat stress, some people participate in meditation practices. A number of studies, across bo...
AUG 21, 2019
Drug Discovery
AUG 21, 2019
Type 2 Diabetic Drug Reverses Heart Failure
In a study published in the Journal of American Cardiology, a drug used for the treatment of diabetes—empagliflozin—was shown to improve the he...
AUG 21, 2019
Cardiology
AUG 21, 2019
New Noninvasive Method For Controlling Atrial Fibrillation
Atrial fibrillation or Afib is a condition in which the heartbeat is irregular. Often the pulse is rapid in Afib patients as the heart attempts to maintain...
AUG 21, 2019
Cardiology
AUG 21, 2019
Shocking Numbers Of People Self-Prescribing Daily Aspirin
Up until recently, people who were concerned about the possibility of suffering a cardiac event were often advised to take low-dose aspirin daily. Because ...
AUG 21, 2019
Drug Discovery
AUG 21, 2019
Novel Drug Target for Dilating Microvessels
Medical scientists at Augusta University have discovered a natural occurring chemical that dilates blood vessels dilate as well as signaling larger blood v...
Loading Comments...